Algeta

Contact
algeta.no
+4723007990

Algeta ASA

Kjelsasveien 172 A, PO Box 54 Kjelsas
0411 Oslo
Norway
+4723007990
algeta.no
Contact
Profile Products News
Contact

About Algeta

Algeta is a Norwegian therapeutics company focused on the development of alpha particle emitters as radiopharmaceuticals for the treatment of cancer.

The Company is targeting metastatic and disseminated tumor types for which there is substantial unmet medical need.

Its first product candidate Alpharadin is targeting skeletal metastases resulting from prostate and breast cancer and is being prepared to enter Phase III clinical trials in hormone refractory prostate cancer.

Read more about Algeta
Facts about Algeta
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of Algeta

Product portfolio

Show all

News about Algeta

Algeta

22-Nov-2012 | business & finance

Ablynx and Algeta enter into collaboration to evaluate Thorium-277 conjugated to nanobodies

Ablynx and Algeta ASA announce a research collaboration to evaluate a novel Targeted Thorium Conjugate (TTC) based on combining Algeta’s proprietary ...

Read news
Algeta

20-Sep-2012 | business & finance

Algeta US Celebrates Official Opening of Operational Center in Cambridge, MA

Algeta ASA celebrated the official opening of the offices and facilities of Algeta US in Cambridge, Massachusetts.In September 2009, Algeta signed an ...

Read news
Algeta

06-Sep-2012 | business & finance

Cobra Biologics and Algeta Sign Agreement to Manufacture Monoclonal Antibody

Cobra Biologics Ltd and Algeta ASA announced a new contract manufacturing partnership for Algeta’s fourth Targeted Thorium Conjugate (TTC) program. The ...

Read news
Algeta

17-Aug-2012 | research and development

Algeta initiates new R&D program to investigate a Targeted Thorium Conjugate (TTC) against hematological cancers

Algeta ASA announced it has initiated a new research and development program aimed at investigating the effect of a novel Targeted Thorium Conjugate (TTC) ...

Read news
Algeta

05-Jun-2012 | research and development

Algeta's Phase III data confirm overall survival benefit of Alpharadin in men with advanced prostate cancer

Overall survival in Alpharadin arm significantly increased by 44%

Read news
Algeta

03-May-2012 | business & finance

Algeta and Sanofi extend research collaboration evaluating thorium-conjugated tumor-targeting antibody

Algeta ASA announced that its research collaboration with Sanofi (previously Genzyme) has been extended. This collaboration, which was announced in April ...

Read news
Algeta

19-Jan-2012 | people

Jeffrey W. Albers appointed President of Algeta US

Algeta ASA  announced the appointment of Jeffrey W. Albers as President of Algeta US, the Company’s new US commercial operation. He takes up his position ...

Read news
Algeta

28-Sep-2011 | research and development

Alpharadin Significantly Improves Overall Survival for Patients with Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases

Algeta ASA announced results from the phase III ALSYMPCA study with the investigational agent Alpharadin (radium-223 chloride). The study met its primary ...

Read news
Show more news about Algeta

Here you will find Algeta ASA